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Purpose: Combined pituitary hormone deficiency (CPHD) is
characterized by a malformed or underdeveloped pituitary gland
resulting in an impaired pituitary hormone secretion. Several
transcription factors have been described in its etiology, but defects
in known genes account for only a small proportion of cases.
Methods: To identify novel genetic causes for congenital
hypopituitarism, we performed exome-sequencing studies on 10
patients with CPHD and their unaffected parents. Two candidate
genes were sequenced in further 200 patients. Genotype data of
known hypopituitary genes are reviewed.
Results: We discovered 51 likely damaging variants in 38 genes; 12
of the 51 variants represent de novo events (24%); 11 of the 38
genes (29%) were present in the E12.5/E14.5 pituitary transcrip-
tome. Targeted sequencing of two candidate genes, SLC20A1 and
SLC15A4, of the solute carrier membrane transport protein family
in 200 additional patients demonstrated two further variants
predicted as damaging. We also found combinations of de novo
(SLC20A1/SLC15A4) and transmitted variants (GLI2/LHX3) in the
same individuals, leading to the full-blown CPHD phenotype.
Conclusion: These data expand the pituitary target genes
repertoire for diagnostics and further functional studies. Exome
sequencing has identified a combination of rare variants in different
genes that might explain incomplete penetrance in CPHD.
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INTRODUCTION
The pituitary gland is the master endocrine gland of the body,
regulating growth, metabolism, stress response, reproduction,
and homeostasis. The mature organ is composed of two
structures derived from different ectodermal origins: the
adenohypophysis (anterior pituitary, consisting of the anterior
and intermediate lobes) and the neurohypophysis (posterior
lobe). The anterior pituitary secretes several hormones—
growth hormone, thyroid-stimulating hormone, follicle-
stimulating hormone, luteinizing hormone, adrenocortico-
trophic hormone, and prolactin—from five different cell types
that all originate from a single primordial structure, Rathke’s
pouch. The development of the anterior pituitary has been
extensively studied in mice and is highly conserved across
vertebrates, including humans.1,2
In mice it begins with a thickening of the oral ectoderm at
E8.5, forming a definitive Rathke’s pouch at E12.5 as it comes
into contact with the infundibulum, an evagination from the
ventral diencephalon that will form the future posterior lobe.
From E12.5 to E17.5, progenitor cells proliferate and finally
differentiate into the specified hormone-secreting cell types.
The adult anterior gland, which is completely separated from
the oral cavity, is composed of the dorsal intermediate lobe
and the ventral anterior lobe.
Several pathways, including Bmp, Shh, Fgf, Wnt, and Notch
signaling, orchestrate the sequential expression of transcrip-
tion factors and pituitary-relevant genes crucial for Rathke’s
pouch development, including initiation, regional cell iden-
tity, and proliferation, as well as final cellular differentiation
into the five hormone-secreting cell types. Abnormalities
within these processes can result in the reduction or loss of
hormone-secreting cells causing congenital hypopituitarism.
Clinical features of hypopituitarism are variable; the key
symptoms are growth retardation, developmental delay,
delayed puberty and infertility, poor stress response, and
metabolic abnormalities such as hypoglycemia. In addition to
pituitary abnormalities (aplasia or hypoplasia of the anterior
pituitary, ectopic posterior pituitary, absent infundibulum),
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patients can show eye abnormalities or midline defects.3–5
Mutations in some genes—those encoding the transcription
factors PROP1, GLI2, LHX3, LHX4, HESX1, PITX2, SOX2,
SOX3, OTX2, POU1F1, and TBX19—have already been
reported in the etiology of congenital hypopituitarism in
humans, resulting in either loss of one pituitary hormone
(isolated pituitary hormone deficiency), deficiency of two or
more hormones (combined pituitary hormone deficiency,
CPHD), or syndromic disorders such as septo-optic
dysplasia.1,5,6 CPHD has an estimated prevalence of 1 in
8,000 individuals worldwide (https://ghr.nlm.nih.gov/condi
tion/combined-pituitary-hormone-deficiency). Most cases of
CPHD are sporadic; familial inheritance accounts for 5 to
30% of all cases.7 From all genes implicated in the etiology of
CPHD, PROP1 is reported as the most common genetic
cause.1,5,8–12 Yet defects within the known genes only account
for a small percentage of CPHD cases, suggesting that many
of the underlying genes involved in the etiology of CPHD still
have to be identified.13 In this study we aimed to find novel
genetic causes of congenital hypopituitarism in a cohort of
210 patients by performing trio-based exome sequencing on
10 of the patients as a starting point. Following several
filtering steps, a list of candidate genes was compiled. Two
candidate genes were analyzed in a cohort of 200 patients in
more detail, and two further variants in SLC20A1 and
SLC15A4 were identified. In addition, transmitted rare, likely
damaging variants from known CPHD genes were detected.
MATERIALS AND METHODS
Patients and controls
For exome sequencing, 10 CPHD patients (2 females and 8
males) from the Center of Child and Youth Medicine in
Heidelberg and their healthy parents were recruited with their
informed consent. All patients were diagnosed between the
ages of 1 week and 4 years and showed growth hormone and
thyroid-stimulating hormone deficiency. Additionally, adre-
nocorticotrophic hormone and/or follicle-stimulating hor-
mone/luteinizing hormone deficiencies were detected in 9 and
7 patients, respectively. None of the patients showed a
prolactin deficiency, measured via immunoassay (basal and/or
after thyrotropin-releasing hormone stimulation). Magnetic
resonance imaging revealed abnormal brain morphologies,
including aplasia or hypoplasia of the adenohypophysis (all
cases), ectopic neurohypophysis (9 cases), and an aplastic
infundibulum (7 cases). The sella turcica was aplastic in one
patient and the nervus opticus hypoplastic in another. DNA
was extracted from peripheral blood leukocytes using the
salting-out method. In total, 30 (patients and parents) samples
were exome-sequenced.
For targeted sequencing, DNA from 200 patients was
provided by R.W.P., with their informed consent. Twenty-
four percent of these patients presented the refined sub-
phenotype CPHD plus ectopic posterior pituitary. Sequencing
data from the Exome Variant Server (the National Heart,
Lung, and Blood Institute’s “Grand Opportunity” Exome
Sequencing Project (ESP), Seattle, WA (http://evs.gs.washing
ton.edu/EVS/)) and 1000 Genomes (http://www.1000gen
omes.org/)14 were used as controls.
Exome sequencing and filtering
The Agilent SureSelect Human All Exon V4 (without untran-
slated regions) was used to capture the exons. Sequencing was
done using the Illumina HiSeq 2000 system (Illumina GmbH,
Münschen, Germany). The raw sequence data were mapped
to the 1000 Genomes phase II reference genome (hs37d5)
using Burrows–Wheeler Aligner 0.6.2, and the duplicates were
removed using PICARD. The 30 samples showed an average
exon coverage of 95.872x and a median-of-median exon
coverage of 90.32x. 99.904% of exons showed non-zero
coverage and 99.252% of exons had at least 10x coverage. On
average, the bases in the target regions with QUAL > 1
showed a coverage of 105.575x with 99.026% showing a
minimum of 10x coverage and 97.068% a minimum 20x
coverage. The single-nucleotide variants (SNVs) were called
by SAMtools on individual samples and the respective parent
information was merged later. Indels were then called along
with parent samples using Platypus. In-house pipelines were
used to annotate the variants with two databases: the National
Center for Biotechnology Information’s dbSNP (https://www.
ncbi.nlm.nih.gov/projects/SNP) and 1000 Genomes. ANNO-
VAR and RefSeq (downloaded on 20 February 2011) were
used for the functional annotation of the variants.
For further analysis, SNVs and indels with a read depth of at
least 10× and minimum QUAL score of 20 were considered.
Nonsynonymous (missense, stop gain, stop loss) and splice
site–affecting SNVs as well as all exonic indels were filtered
further. Custom variant allele frequency (VAF) thresholds were
used to assign genotypes to the SNVs. For SNVs to be
heterozygous, they should have a minimum of 15% VAF and a
maximum of 90% VAF. SNVs with VAF of 95% and above
were considered homozygous alternate and those with VAF of
5% and below were considered homozygous reference. For
indels, the genotype predicted by Platypus was used.
The minor allele frequency (MAF) from 1000 Genomes was
used to define the variant’s rareness in the population.
Variants with MAF > 1% were removed (removal of
compound heterozygous variants if MAF of one allele
> 1%). Furthermore, a set of 45 exomes from the in-house
database was used as control to remove common variants and
sequencing artifacts (removal of compound heterozygous
variants if one or both alleles was found in in-house controls).
The functional effect of the remaining variants was
predicted using the in silico prediction tools MutationTaster,
SIFT, PolyPhen2, PROVEAN, and CADD. Variants that were
predicted as damaging by at least one in silico prediction tool
were used for further analysis. Compound heterozygous
variants were included only if both variants are predicted as
damaging by at least one prediction tool.
Pituitary complementary DNA libraries
Data for two complementary DNA (cDNA) libraries gener-
ated from embryonic mouse Rathke’s pouch material are
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publicly available from the National Center for Biotechnology
Information (UniGene Library Browser).6,15
E12.5: UniGene, RIKEN full-length enriched mouse cDNA
library, Rathke’s pouches 12.5 days embryo, library ID:
Lib.18109
E14.5: UniGene, RIKEN full-length enriched mouse cDNA
library, CD-1 Rathke’s pouches 14.5 days embryo, library ID:
Lib.18113
Sanger sequencing
All variants in genes present in the cDNA libraries were
confirmed by Sanger sequencing. Polymerase chain reaction
was performed with Paq5000 Polymerase (Stratagene, Wald-
bronn, Germany) or HotStarTaq DNA Polymerase (Qiagen,
Hilden, Germany). Generated polymerase chain reaction
products were analyzed on agarose gels, purified, and
sequenced directly using the DYEnamic ET Terminator Cycle
Sequencing Kit (GE Healthcare, Rimbach, Germany) and the
MegaBACE 1000 DNA Analysis System (GE Healthcare). For
sequencing the coding region of SLC20A1 and SLC15A4,
polymerase chain reaction products of exonic amplicons were
generated using Paq5000 Polymerase (Stratagene) and subse-
quently sequenced (GATC, Konstanz, Germany). All primer
sequences used are listed in Supplementary Table S1 online.
Pathway analysis
To identify relevant biological pathways implicating those
genes identified, we applied Ingenuity Pathway Analysis (IPA)
methodology (IPA Software, Ingenuity Systems, http://www.
ingenuity.com). IPA integrates selected omics data sets
Raw reads
BWA alignment to reference human genome
(hs37d5)
Merge and remove duplicates by PICARD
SNV calling by SAMtools
indel calling by platypus
Annotate variants by dbSNP and 1000 genomes
Functional annotation of variants by ANNOVAR
and RefSeq
Assign genotypes by custom threshold of
variant allele frequency (VAF)
Assign genetic model
Functional effects of genetic variants 
(PROVEAN, MutationTaster, PPH2, SIFT)
10 Patients with panhypopituitarism
Exome sequencing (Illumina HiSeq)
Bioinformatical analysis
Filtered variants for further analysis:
Non-synonymous, splice site affecting
SNVs and exonic indels:
≥ 10 reads, QUAL score ≥ 20
Minor allele frequency (MAF) of ≥ 1%
in 1000 Genomes and not in in-house
controls
Leads to ~400 candidate genes per patient
Removal of transmitted single
heterozygous variants
Predicted as damaging by at least one
prediction program
CADD Score, gnomAD Browser
Comparison to transcriptome of mouse
E12.5 and E14.5 Rathke′s pouch
Sequencing 200 patients
Comparison with 13 known human
congenital hypopituitarism genes
3/10 patients with variants in GLI2 and/ or LHX3
transmitted from unaffected parents
a b
Figure 1 Strategy for identifying candidate genes involved in pituitary gland development. Pipeline of exome sequencing and filtering and
two approaches (a) and (b) to analyzing nontransmitted and transmitted variants. BWA, Burrows–Wheeler Aligner; SNV, single-nucleotide variant.
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(genomics, transcriptomics, miRNAomics, proteomics) with
mining techniques to predict functional connections and their
interpretation in the context of protein networks that
comprise protein–protein interactions and related biological
functions and canonical signaling pathways.
RESULTS
Exome sequencing
To identify new candidate genes implicated in the etiology of
congenital hypopituitarism, a cohort of 210 patients was
collected. First, exome sequencing on 10 probands (2 females,
8 males; Supplementary Table S2) and their unaffected
parents (total: 30 samples) was performed.
Exonic sequences were enriched using SureSelect (Agilent)
for targeted exon capture and paired-end sequenced with the
Illumina HiSeq 2000 system. The raw sequence data were
mapped to the 1000 Genomes phase II reference genome
(hs37d5) followed by a bioinformatic variant detection
pipeline (see Materials and Methods and Figure 1). On
average, we obtained high exon coverage of 95.872 × for all 30
samples demonstrating good quality of the sequence data. Of
all exons, 99.904% were covered (nonzero coverage) and
99.252% were assessed by at least 10 independent reads.
For our analyses only nonsynonymous (missense, stop gain,
stop loss) and splice site–affecting SNVs as well as all exonic
indels were filtered further. We considered SNVs and indels
inherited de novo; homozygous, heterozygous, hemizygous, or
compound heterozygous showing ≥ 10 independent reads;
and a minimum QUAL score of 20. Variants annotated in
1000 Genomes with a MAF of ≤ 1% or found in sequence data
of an in-house control group were excluded. This resulted in
approximately 400 candidate genes per patient. Variants were
then analyzed on their effect on protein function and were
considered for further analysis if they were predicted as
damaging by at least one of the prediction tools used (SNVs:
PROVEAN, MutationTaster, PPH2, SIFT; indels: PROVEAN,
MutationTaster, SIFT) (Figure 1a). Applying these criteria,
we searched for rare highly penetrant causative variants and
revealed a total number of 51 variants in 38 genes and an
average number of 3.8 candidate genes (5.1 variants) for each
patient (Supplementary Table S3).
IPA network analysis
To further address the biological relevance of our results, IPA
was first used on all known 22 human and mouse genes
underlying combined pituitary hormone from the literature.
The newly identified 38 candidate genes were then integrated
to predict functional connections in the context of the known
protein networks. In this analysis, 6 of the 38 identified genes
could be integrated in the existing networks (SLC20A1, TET2,
AGAP1, BODL1, MAMLD1, and ITGA2B; from 3 patients)
(Figure 2). Key nodules turned out to be the two transcription
factor encoding genes, SOX2 and GATA2, and the nuclear
receptor gene NR5A1.16,17 SOX2 interacts with BOD1L1,
which indirectly activates AGAP1.18 SOX2 also interacts with
NR5A1, which activates MAMLD119,20 and it also activates
TET2, which indirectly activates AGAP1.21,22 The
transcription factor GATA2 interacts with SLC20A1 and
activates ITGA2B; TET2 activates not only AGAP1 but also
SLC20A1.23 Together, these data link variants in several novel
candidate genes with the SOX2 and GATA2 networks, which
have a validated role in pituitary development and individuals
with CPHD.24–26 Interestingly, three of the novel candidates
(SLC20A1, TET2, AGAP1) are derived from patient RaKi_40;
two candidates, BOD1L1 and MAMLD1, are connected with
SOX2 and are derived from patient RaKi_51; and ITGA2B is
from patient RaKi_42.
Identification of pituitary-relevant genes
As all patients showed aplastic or hypoplastic adenohypo-
physes, indicating that disruption of proliferative processes
during pituitary development was likely, we searched for
additional evidence that the identified candidate genes were
transcribed in the developing pituitary. A phase of massive
cell proliferation occurs from E12.5 to E14.5 of mouse
pituitary development, which prompted us to analyze the
presence or absence of the 38 candidate genes in cDNA
library data from mouse wild-type Rathke’s pouches at
embryonic stage E12.5 and E14.5.6,15 Using this approach, a
total of 11 genes, including SLC20A1 and SLC15A4, were
found to be expressed at E12.5 or E14.5 or both (Table 1). All





























Figure 2 Ingenuity Pathway Analysis (IPA) Network Analysis. All
known human (yellow) and mouse (green) genes from the literature
underlying combined pituitary hormone deficiency and congenital
pituitary malformation were analyzed using the IPA network analysis. The
newly identified 38 candidate genes were added to predict functional
connections in the context of the known protein networks. Six (orange)
of the 38 identified candidate genes could be integrated in the existing
networks.
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Sanger sequencing. Variants were either de novo (4 genes), or
inherited homozygous (3 genes), hemizygous (3 genes), or
compound heterozygous (1 gene), leading to a frameshift in
one gene or to a single amino acid exchange in the
remaining genes.
Sequencing SLC20A1 and SLC15A4 in a large CPHD patient
cohort
Exome sequencing has discovered de novo missense variants
in SLC20A1 (L89S, patient RaKi_40) and SLC15A4 (P456L,
patient RaKi_54), two members of the solute carrier (SLC)
group of membrane transport proteins (Supplementary
Table S3, Table 2). To gain further evidence for a causative
pathogenic effect in CPHD, we selected SLC20A1 and
SLC15A4 as candidate genes for sequence analysis in an
additional 200 patients. The two candidate genes were
selected for the following reasons: (i) de novo variants, (ii)
variants predicted as damaging by all used prediction tools
(PPH2, PROVEAN, SIFT, MutationTaster), (iii) high CADD
scores of 22.5 and 31.0, (iv) found in neither SNP (dbSNP)
nor large population exome/genome sequencing databases
(1000 Genomes, Exome Variant Server, and gnomAD
database (http://gnomad.broadinstitute.org)), and (v)
expressed in the E12.5 or E14.5 pituitary transcriptome
(Table 1,Supplementary Table S3).
Sequence analysis of SLC20A1 identified one additional
unrelated patient (511) with a variant resulting in an amino
acid exchange from leucine to phenylalanine (L521F), which
was predicted as damaging by all prediction tools (CADD
score 28.9) and was absent in population databases (Table 2).
Further SLC20A1 variants identified in other patients likely
present nonpathogenic variants (Table 2). Sequence analysis
of SLC15A4 also identified one additional unrelated patient
(1801) with a variant predicted as damaging by two of the
four prediction tools used (CADD score 15.9), resulting in an
amino acid exchange from leucine to phenylalanine (L84F)—
a variant that was absent in public population databases (e.g.,
the gnomAD server) (Table 2). In total, likely pathogenic
Table 1 Candidate genes detected in the transcriptome of
E12.5 and/or E14.5 mouse Rathke’s pouch
Patient ID Gene Genetic model E12.5 E14.5
RaKi_30 PALLD Compound heterozygous √
RaKi_36 POLR3D De novo √
RaKi_40 SLC20A1 De novo √ √
RaKi_42 IRS4 Hemizygous √ √
TSPYL2 Hemizygous √
C16orf 91 Homozygous √ √
RaKi_46 ATP13A1 Homozygous √
RaKi_49 PPRC1 Homozygous √
RaKi_50 MYO9B De novo √ √
RaKi_54 SLC15A4 De novo √
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variants were identified in 2 additional patients out of 200
cases analyzed, reflecting the complex nature of this disorder.
Inherited variants of known CPHD genes from
asymptomatic parents
To also determine whether any variants from the known
hypopituitary genes were transmitted from the unaffected
parents to the affected children, we applied a second
approach and went back to the initial 400 candidate genes
per patient (Figure 1b). To our surprise, three patients
carried likely damaging variants in the GLI2 and LHX3
genes,27,28 with CADD scores ranging between 15 and 33
(RaKi_40, RaKi_50, and RaKi_54) (Table 3). We reviewed
gnomAD read-level evidence for every rare variant. Pre-
viously published LHX3 and GLI2 mutations showed CADD
scores ranging between 9 and 34 for missense mutations in
GLI2 and between 6 and 28 in LHX3 (Supplementary Table
S4), suggesting that the variants identified in our study are
also likely pathogenic. Whereas all patients with LHX3
mutations mentioned to date have been homozygous or
compound heterozygous, most GLI2 variants associated to
CPHD have been heterozygous with incomplete penetrance.
The GLI2 variant was found in the asymptomatic father and
the patient RaKi_40, but the patient also showed the de novo
SLC20A1 (L89S) variant, suggesting that the added effect of the
two variants led to the clinical phenotype (Supplementary
Figure 1). The same was also true for the asymptomatic father
of patient RaKi_54, who carried the same LHX3 variant as his
affected child, but only the child additionally presented the
SLC15A4 (P456L) variant. The third patient, RaKi_50, had a
combination of a likely damaging GLI2 and a LHX3 variant;
the GLI2 variant was transmitted from the asymptomatic father
and the LHX3 variant from the asymptomatic mother
(Supplementary Figure 1, Table 3).
In RaKi_51, a variant leading to a frameshift (p.
S15Kfs*41) in the recently published hypopituitary gene
TCF7L1 was transmitted from the unaffected mother to the
affected child. Both mother and son RaKi_51 carried this
rare variant, which is not annotated in the gnomAD
database, strongly suggesting that it contributes to function;
in the son possibly in concert with a de novo mutation in
the NOBOX gene.29
DISCUSSION
Over the past two decades our knowledge of the genes
important in pituitary development mainly came from the
study of animal models. In these models, defective genes
encoding transcription factors and signaling molecules for
organ commitment, cell differentiation, and proliferation
could be identified. In humans, mutations in PROP1,
POU1F1, HESX1, GLI2, LHX3 and LHX4, and others have
been subsequently demonstrated in patients with CPHD,
associated with severe forms of short stature, together with a
remarkable variability in the overall clinical manifestation. In
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etiology has remained unexplained, suggesting the involve-
ment of additional genes in pituitary ontogeny.
Whole-exome sequencing now provides the opportunity to
identify novel genes implicated in hypopituitarism indepen-
dent of preceding animal studies.30 To identify novel
candidate genes associated with CPHD, we started out with
high-quality exome-sequencing data from 30 individuals (10
patients and their unaffected parents). A filtering pipeline
resulted in a first list of on average 3.8 candidate genes per
patient. None of the known genes associated with hypopitui-
tarism were found using this approach. A comparison with
cDNA library data from embryonic mouse Rathke’s pouches
showed that several of these candidate genes, including
SLC20A1 and SLC15A4, were expressed in Rathke’s pouch
tissue during early stages of pituitary development. Bearing in
mind the limitations of cDNA library construction and the
possible differences between human and murine pituitary
organogenesis, the absence of a gene in these databases does
not necessarily mean that it is not expressed in the pituitary at
this particular developmental stage. For this reason, the other
genes still represent possible candidates for CPHD.
Taking advantage of the trio-based approach (patients and
unaffected parents), de novo variants were of particular
interest. Using the pituitary transcriptome filter, four genes
remained as candidates, inherited de novo. Given the
oligogenic nature of CPHD and low recurrence rate of
mutations among CPHD genes, we selected and sequenced
SLC20A1 and SLC15A4 in additional 200 patients. These
large-scale resequencing studies identified another likely
pathogenic variant in SLC20A1 and one further likely
pathogenic variant in SLC15A4.
SLC20A1 and SLC15A4 belong to the SLC group of
membrane oligopeptide transporter superfamily.31 Most
members, including SLC20A1 and SLC15A4, are located in
the cell membrane. The SLC20 family transport proteins
function as sodium phosphate cotransporters across the
plasma membrane. SLC20A1 is expressed ubiquitously in all
tissues and although generally considered housekeeping
transport proteins, the discovery of tissue-specific activity,
regulatory pathways, and gene-related pathophysiologies is
redefining their importance.32 A Slc20a1 knockout mouse is
embryonically lethal.33 We have identified two SLC20A1
variants, L89S and L521F, with high CADD scores in two
unrelated individuals (Table 2). The variants reside in exon 1
and exon 7 in positions that are highly conserved between
vertebrates; L521F was even conserved down to Drosophila.
Members of the SLC15A4 family are using proton motive
force for uphill transport of free histidine and certain di- and
tripeptides from the endosome to the cytoplasm.27 They are
predicted to contain 12 transmembrane domains with N- and
C-termini facing the cytosol mediating the uptake and
reabsorption of protein digestion products into the intestine
and kidney, and function in neuropeptide homeostasis in the
brain.34 Unlike other members of the SLC15 family not much
is known about the function of SLC15A4 in the brain.35,36 In
the adult rat brain, Slc15a4 has been shown to be widely
distributed and it can be detected in the hippocampus,
cerebellum, pontine nucleus, cerebral cortex, brain stem,
thalamus, and hypothalamus in neuronal and nonneuronal
cells. It has been suggested that Slc15a4 functions in removal
of degraded neuropeptides, e.g., neuromodulators from the
synaptic cleft, as well as controls the uptake of oligopeptides
to regulate the cellular metabolism in the central nervous
system.36 A knockout mouse revealed no significant differ-
ences between wild type in serum chemistry, body weight,
viability, and fertility.37 The variant P456L detected in one of
our CPHD patients is located within a small loop between the
transmembrane domains (TMD) 9 and 10 close to TMD10.
The affected amino acid Pro is highly conserved within
vertebrates as well as within the SLC15 family and was
predicted as damaging by all prediction programs used in this
study. The variant L84F resides in the TMD2 and was also
predicted to affect protein function. How these variants affect
protein structure and function in the brain linked to pituitary
development will need to be elucidated in future studies.
These studies may not be trivial, as only the combined
analysis of all variants in one individual may lead to the
deleterious consequences.
Large-scale genotyping and sequencing methods and access
to large-scale population control exomes have only now
allowed unbiased assessments of penetrance in population
controls. In a second approach (Figure 1b), we raised the
question whether likely damaging variants of known genes
underlying CPHD have been transmitted from unaffected
parents to affected children. When we went back to the initial
set of 400 genes per patient and asked which likely damaging
gene variants are shared between children and parents, we
were surprised to detect that 3 of the 10 exome-sequenced
patients also carried likely damaging variants in the GLI2 and
LHX3 genes. Several variants of these genes have strong
contextual support from preexisting genetic data.27,28 Hetero-
zygous GLI2 mutations have been identified relatively
frequently (17%) especially in patients with CPHD and an
ectopic posterior pituitary lobe,38 while LHX3 mutations were
found less frequently and all in homozygous state
(Supplementary Table S4).27,28 We also identified a
frameshift in the hypopituitary gene TCF7L1 (p.S15Kfs*41),
transmitted from an unaffected mother to her son (RaKi_51),
suggesting that this variant, possibly in concert with the de
novo mutation in NOBOX, contributes to the CPHD
phenotype in her son.29
In our study we focused on variants that are extremely rare
or absent in the large contemporary multiethnic sequencing
databases (e.g., gnomAD) (e.g., variants in SLC20A1 and
SLC15A4), as we initially argued that a fully penetrant disease
genotype should be no more common in the population than
the disease that it causes. Likely damaging variants in these
two candidate genes were also found in further 2 out of 200
patients, making it extremely likely that the variants are
causative from a statistical perspective compared with
individuals from the gnomAD server (0/55,607 individuals
for the L89S variant of SLC20A1; 0/7506 individuals for the
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SLC15A4 P456L variant, and no data for the L521F variant of
SLC20A1 and L84F variant of SLC15A4). We then provided
additional evidence from variant prediction tools, pituitary
transcriptomics, and IPA network analysis. Our analysis
shows that the phenotype is derived from the combination of
variants in more than one gene (oligogenic inheritance) and
from a combination of both transmitted and de novo
occurring variants in individual patients. Digenic inheritance
in patients with CPHD did not come as a complete surprise
and has been reported before.39
The novelty of our study is that in (at least) three of the
exome-sequenced patients more than one gene contributed to
the phenotype and that this oligogenic situation was a
combination of rare de novo variants and transmitted
variants. In patient RaKi_40, it may even be possible that,
besides the likely damaging gene variant in SLC20A1 and the
transmitted GLI2 variant, possibly damaging variants in the
TET2 and AGAP1 genes (Supplementary Table S3) may
contribute to the phenotype. All of these candidate genes are
connected and activated via SOX2 (Figure 2).17,22 Mutations
in SOX2 have a validated role in individuals with CPHD.26
Given the complexity of the issue, our exome data have
opened new avenues and provided further evidence that
CPHD is a genetically complex disorder with incomplete
penetrance and variable expressivity.
Conclusion
In this report we demonstrate whole-exome sequencing as a
successful approach to identify novel candidate genes under-
lying congenital hypopituitarism. Our study has provided new
genetic risk loci for CPHD, which will contribute to the
diagnostics of hypopituitarism as well as help to elucidate the
molecular mechanisms underlying pituitary development. We
have demonstrated that a combination of de novo and
transmitted variants can occur in the same individuals and
may contribute to the clinical phenotype in patients with
CPHD. It is therefore possible that a combination of different
gene variants is needed to lead to the full-blown phenotype.
Locus-based sequencing strategies are not digging deep
enough to reveal the overall pattern of alterations in this
disorder and are not enough to evaluate diagnostic disease
risk. Exome sequencing will remain the method of choice to
provide sufficiently large data sets in disorders with
incomplete penetrance and variable expressivity to allow a
global genome-based view of all exonic genetic alterations.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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